CoChat

Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK

Open access
Thalange, Nandu, Gundgaard, Jens, Parekh, Witesh, Tutkunkardas, Deniz · 2019 · BMJ Open Diabetes Research & Care

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Objective: With healthcare systems under increasing financial pressure from costs associated with diabetes care, it is important to assess which treatments provide clinical benefits and represent best value. This study evaluated the annual costs of insulin degludec (degludec) versus insulin detemir (IDet) in children and adolescents with type 1 diabetes (T1D) in the UK. Research design and methods: Using data from a randomized, treat-to-target, non-inferiority trial—BEGIN YOUNG 1—annual costs with degludec versus IDet in children and adolescents aged 1–17 years with T1D were estimated, as costs of these insulins and hyperglycemia with ketosis events. Analyses by age group (1–5, 6–11 and 12–17 years) and scenario (no ketosis benefit, no dose benefit, hyperglycemia with ketones >0.6 and >3.0 mmol/L and the additional costs of twice-daily IDet in 64% of patients) were also performed. Results: The mean annual cost per patient was estimated as £235.16 for degludec vs £382.91 for IDet, resulting in an annual saving of £147.75 per patient. These substantial cost savings were driven by relative reductions in the frequency of hyperglycemia with ketosis and basal insulin dose with degludec versus IDet. Annual savings in favor of degludec were observed across each age group (£122.63, £140.59 and £172.50 for 1–5, 6–11 and 12–17 years age groups, respectively). Five scenario analyses further demonstrated the robustness of the results, which included no ketosis or dose benefits in favor of degludec. Conclusions: Degludec provides appreciable annual cost savings compared with IDet in children and adolescents with T1D in a UK setting. While a cost-effectiveness analysis could incorporate the health impact of treatment complications better than the present cost analysis, the strong generalizability of the data from this study suggests that degludec can help healthcare providers to maximize health outcomes despite increasingly stringent budgets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjdrc-2019-000664

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Direct costs associated with hyperglycemia with ketosis events in children and adolescents treated at (A) home only £43.19 and (B) home and NHS facilities £373.53. NHS, National Health Service.
Figure 1 Direct costs associated with hyperglycemia with ketosis events in children and adolescents treated at (A) home only £43.19 and (B) home and NHS facilities £373.53. NHS, National Health Service.CC BY · PubMed Central
Figure 2 Main cost analysis of degludec compared with IDet in children and adolescents with type 1 diabetes. IDet, insulin detemir.
Figure 2 Main cost analysis of degludec compared with IDet in children and adolescents with type 1 diabetes. IDet, insulin detemir.CC BY · PubMed Central
Figure 3 Age group analyses of degludec compared with IDet in children and adolescents with type 1 diabetes. IDet, insulin detemir.
Figure 3 Age group analyses of degludec compared with IDet in children and adolescents with type 1 diabetes. IDet, insulin detemir.CC BY · PubMed Central
Figure 4 Scenario analyses of degludec compared with IDet in children and adolescents with type 1 diabetes. IDet, insulin detemir.
Figure 4 Scenario analyses of degludec compared with IDet in children and adolescents with type 1 diabetes. IDet, insulin detemir.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 7

Metadata

Authors
Thalange, N., Gundgaard, J., Parekh, W., & Tutkunkardas, D.
Affiliations
  • Al Jalila Foundation (AE)
  • Novo Nordisk (Denmark) (DK)
  • Novo Nordisk (United Kingdom) (GB)
Corresponding author
Thalange, Nandu
Venue
BMJ Open Diabetes Research & Care
Publisher
BMJ
Published
2019-09
Volume
7
Issue
1
Pages
e000664
ISSN
2052-4897 (ISSN-L)
OpenAlex
W2971955106
Cited by
7
References
25
Citations by year
2022: 1 · 2021: 5 · 2020: 1
FWCI
1.42
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • BMJ Open Diabetes Research & Care (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Novo Nordisk A/S
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
insulin degludec, insulin detemir, type 1 diabetes, children and adolescents, cost analysis, basal insulin dose, cost reduction, insulin analogues, treatment cost comparison
MeSH terms
Insulin Detemir, Adolescent, Blood Glucose, Child, Child, Preschool, Cost-Benefit Analysis, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, United Kingdom, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Infant, Male, Prognosis, Biomarkers, Insulin, Long-Acting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK. https://app.cochat.ai/papers/10.1136/bmjdrc-2019-000664
The paper
Thalange, N., Gundgaard, J., Parekh, W., & Tutkunkardas, D. (2019). Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK. BMJ Open Diabetes Research & Care. https://doi.org/10.1136/bmjdrc-2019-000664

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.